Market Trend Insights: The Impact of Recent Advances on the Customized Genetic Testing Market

The customized genetic testing market is gaining significant traction as advances in genomics continue to transform healthcare. With growing interest in personalized treatment plans and risk assessments, this sector is set to experience remarkable expansion in the years ahead. Let's explore the market's projected size, the main players shaping its future, emerging trends, and the key segments defining this evolving industry.

Projected Market Size and Growth Outlook for Customized Genetic Testing
The customized genetic testing market is anticipated to expand rapidly, reaching a valuation of $29.5 billion by 2030. This growth corresponds to an impressive compound annual growth rate (CAGR) of 15.8%. Several factors are driving this surge, including a rising demand for personalized medicine, greater incorporation of genomics into routine healthcare practices, and the growing emphasis on preventive healthcare. Additionally, increased adoption of precision oncology and substantial investments in genomic data platforms are contributing to the market's robust outlook. Key trends forecasted to influence this expansion include wider use of personalized genetic panels, more frequent application of next-generation sequencing (NGS) based customized tests, greater pharmacogenomic applications, heightened focus on targeted risk assessments, and improved integration with clinical decision support tools.

Download a free sample of the customized genetic testing market report:
https://www.thebusinessresearchcompany.com/report/customized-genetic-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Shaping the Customized Genetic Testing Landscape
The customized genetic testing market features several prominent organizations that are advancing innovations and expanding service offerings. Leading firms include Guardant Health, Tempus, Invitae, 23andMe, Labcorp, Quest Diagnostics, Revvity Omics (PerkinElmer Genomics), Natera, Myriad Genetics, BGI Genomics, CENTOGENE, Veracyte, Fulgent Genetics, LetsGetChecked, Helix, MedGenome, Baylor Genetics, Prenetics, Eurofins (Clinical Genetics), Mapmygenome, and Nebula Genomics. These players are actively involved in developing new testing technologies and expanding access to personalized genetic insights.

Strategic Moves Reinforcing Market Position
In March 2025, Tempus, a U.S.-based precision medicine company, completed the acquisition of Ambry Genetics for an undisclosed amount. This strategic acquisition aims to strengthen Tempus' position in the customized genetic testing arena by combining Ambry's expertise in inherited disease diagnostics with Tempus' AI-driven precision medicine platform. Ambry Genetics specializes in clinical genetic testing, focusing on inherited diseases, cancer risk evaluation, and next-generation sequencing solutions to support precision healthcare. The deal enhances Tempus' technological capabilities and broadens its market reach.

The customized genetic testing market is gaining significant traction as advances in genomics continue to transform healthcare. With growing interest in personalized treatment plans and risk assessments, this sector is set to experience remarkable expansion in the years ahead. Let's explore the market's projected size, the main players shaping its future, emerging trends, and the key segments defining this evolving industry.

Projected Market Size and Growth Outlook for Customized Genetic Testing
The customized genetic testing market is anticipated to expand rapidly, reaching a valuation of $29.5 billion by 2030. This growth corresponds to an impressive compound annual growth rate (CAGR) of 15.8%. Several factors are driving this surge, including a rising demand for personalized medicine, greater incorporation of genomics into routine healthcare practices, and the growing emphasis on preventive healthcare. Additionally, increased adoption of precision oncology and substantial investments in genomic data platforms are contributing to the market's robust outlook. Key trends forecasted to influence this expansion include wider use of personalized genetic panels, more frequent application of next-generation sequencing (NGS) based customized tests, greater pharmacogenomic applications, heightened focus on targeted risk assessments, and improved integration with clinical decision support tools.

Download a free sample of the customized genetic testing market report:
https://www.thebusinessresearchcompany.com/report/customized-genetic-testing-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Shaping the Customized Genetic Testing Landscape
The customized genetic testing market features several prominent organizations that are advancing innovations and expanding service offerings. Leading firms include Guardant Health, Tempus, Invitae, 23andMe, Labcorp, Quest Diagnostics, Revvity Omics (PerkinElmer Genomics), Natera, Myriad Genetics, BGI Genomics, CENTOGENE, Veracyte, Fulgent Genetics, LetsGetChecked, Helix, MedGenome, Baylor Genetics, Prenetics, Eurofins (Clinical Genetics), Mapmygenome, and Nebula Genomics. These players are actively involved in developing new testing technologies and expanding access to personalized genetic insights.

Strategic Moves Reinforcing Market Position
In March 2025, Tempus, a U.S.-based precision medicine company, completed the acquisition of Ambry Genetics for an undisclosed amount. This strategic acquisition aims to strengthen Tempus' position in the customized genetic testing arena by combining Ambry's expertise in inherited disease diagnostics with Tempus' AI-driven precision medicine platform. Ambry Genetics specializes in clinical genetic testing, focusing on inherited diseases, cancer risk evaluation, and next-generation sequencing solutions to support precision healthcare. The deal enhances Tempus' technological capabilities and broadens its market reach.

Technological Innovations Driving Advances in Customized Genetic Testing
Companies active in this market are emphasizing material science breakthroughs and device innovation to improve testing accuracy and patient outcomes. For example, there is a notable focus on polymer-based neurovascular stents that enhance biocompatibility, encourage vessel healing, and reduce reliance on long-term anticoagulants. In June 2023, Canadian start-up Fluid Biomed achieved a milestone by implanting the world's first polymer-based neurovascular stent in human patients. Branded the ReSolv stent, it targets brain aneurysms and differs from conventional hybrid polymer-metal stents by being fully polymer-based and designed to dissolve gradually as the vessel heals. This pioneering design offers potential benefits such as minimizing the need for extended blood-thinning medication while supporting natural recovery.

Detailed Segmentation of the Customized Genetic Testing Market
This market report categorizes customized genetic testing into distinct segments to provide a comprehensive understanding:

1) Test Type: Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing
2) Sample Type: Saliva, Blood, Buccal Swab
3) Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray Analysis, Single-Cell Sequencing
4) Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Metabolic Disorders
5) End-User: Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing

Specific subcategories include:
- Predictive Testing covering cancer susceptibility, neurodegenerative disorders, cardiovascular risk, and metabolic disorder risks
- Carrier Testing focused on conditions like cystic fibrosis, sickle cell anemia, Tay-Sachs disease, and thalassemia
- Prenatal and Newborn Testing including non-invasive prenatal testing (NIPT), newborn screening panels, chorionic villus sampling (CVS), and amniocentesis-based tests
- Diagnostic Testing related to rare diseases, oncology genetics, neurological disorders, and infectious disease-related genetic testing
- Pharmacogenomic Testing targeting drug metabolism, oncology, cardiovascular responses, and psychiatric drug efficacy

This structured segmentation helps stakeholders identify niche opportunities and tailor solutions to meet specific clinical and consumer needs within the customized genetic testing market.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.